BPI-21668

BPI-21668 is an orally bioavailable, potent, and selective small molecule inhibitor of the alpha isoform of phosphoinositide 3-kinase (PI3Kα), developed by Betta Pharmaceuticals. It is designed to target tumors harboring PIK3CA mutations, which are common drivers in various solid malignancies, including breast, lung, and colorectal cancers. By inhibiting PI3Kα, BPI-21668 blocks the PI3K/AKT/mTOR signaling pathway, thereby suppressing tumor cell proliferation and survival. It is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors, particularly those with documented PIK3CA mutations.